1
Sierra David H, Luck Edward E, Brown Dennis M: Surgical adhesive material.. Project Hear, Matrix Pharma, November 8, 1989: EP0341007-A2 (42 worldwide citation)

The present invention provides a surgical adhesive comprising, in an aqueous composition, patient autogenous plasma, collagen, thrombin, and optionally, an antifibrinolytic agent. The present adhesive is formed from the patient's plasma without the use of any added reagents for concentration or isol ...


2
Sierra David H, Luck Edward E, Brown Dennis M: Fibrin/collagen membrane material for biomedical use.. Matrix Pharma, May 13, 1992: EP0485210-A2 (29 worldwide citation)

Gel membranes are provided by gelling fibrinogen with thrombin by itself or in combination with gelation of collagen. After dehydration, the resulting membranes may be used as dressings, temporary skin grafts, or the like. The gels may be used without dehydration for drug delivery or tissue regenera ...


3
Luck Edward E, Brown Dennis M: Compostions for treating intracranial tumors.. Matrix Pharma, August 16, 1989: EP0328389-A2 (4 worldwide citation)

Intracranial abnormal solid cellular masses, particularly tumors or adjacent tissues that may contain tumor cells, are treated by administering to the abnormal area a sufficient amount of a cytotoxic drug comprising a vinca alkaloid dispersed in a stable flowable proteinaceous matrix. The matrix sub ...


4
Brown Dennis M, Luck Edward, Twardzik Daniel R, Purchio Anthony F: (b) Protein compositions for inhibition of cell proliferation.. Oncogen, Matrix Pharma, May 20, 1992: EP0485530-A1

Antiproliferative compositions are provided which are capable of sustained release of an antiproliferative agent, particularly a TGF- beta , at a site proximal to a target cell. The compositions are effective in inhibiting proliferation of the target cell, particularly when used in combination with ...


5
Roskos Kathleen V, Jones Richard E, Maskiewicz Richard: Improved process and composition for therapeutic cisplatin (cddp). Matrix Pharma, September 2, 1998: EP0861084-A1

An improved diluent for the preparation of cisplatin suspensions from a lyophilized powder is provided. The diluent contains a pharmaceutically acceptable nonionic surfactant, which improves the accuracy and homogeneity of the therapeutic formulation. The suspension may be used directly, or may be u ...


6

7
Singh Saira, Jones Richard E, Brown Dennis M: Use of cell membrane permeants in the treatment of cellular proliferative diseases. Matrix Pharma, March 31, 1999: EP0904074-A1

Methods are provided for the treatment of a host suffering from a cellular proliferative disease through administration of a chemotherapeutic agent in conjunction with a cell membrane permeant. Optionally, the cell membrane permeant and/or chemotherapeutic agent will be present in a pharmaceutically ...


8
Brown Dennis M, Jones Richard E, Maskiewicz Richard, Michaels Shawnya K: Methods and compositions for the treatment of a host with a cellular proliferative disease. Matrix Pharma, October 30, 1996: EP0739210-A1

Methods and compositions are provided for the treatment of a hostwith a cellular proliferative disease, particularly a neoplasia. In the subject methods, a pharmaceutically acceptable, substantially anhydrous, injectable semi-solid composition which acts as a depot for a cytostatic agent, is adminis ...


9
Jones Richard E, Li Mike T: Novel collagen formulations. Matrix Pharma, March 4, 1998: EP0825848-A1

Disclosed are proteinaceous compositions comprising collagen and an effective amount of a compatible cytotoxic drug which compositions are characterized by having a single collagen transition temperature of less than about 45 DEG C. Such compositions possess enhanced retention of the cytotoxic drug ...


10